Osimertinib/osimertinib will be newly launched in 2024, and the medication guide will be interpreted

Osimertinib/osimertinib (Osimertinib) is a new type of targeted therapy drug for the treatment of EGFR (epidermal growth factor receptor) gene mutation-positive advanced non-small cell lung cancer (NSCLC). Its medication guidelines are critical to patient outcomes. The following is a detailed introduction to the medication guide for osimertinib/osimertinib:

1.Indications:Osimertinib/OsimertinibApplicable toEGF Patients with advanced Rgene mutation-positive NSCLC, especially those who are resistant to other EGFR inhibitors. For those who have Del19, L858R or T790Metc.

2.Dosage and Administration:Osimertinib/Osimertinibis usually administered as an oral tablet at a dose of 80 mg (mg) once a day, with or without food. Patients should take Osimertinib on time and in the correct amount under the guidance of a doctor, and should not change the dosage or stop taking the medicine at will.

3.Dosing time: Osimertinib/Osimertinib is usually taken on an empty stomach or 2 hours after a meal to ensure the best absorption of the drug. Patients should swallow the tablets whole and drink them with a sufficient amount of water (approximately 200 milliliters). It is not recommended to chew Osimertinib/Osimertinib tablets or break them in half to avoid affecting the release rate and absorption of the drug.

4.Dose adjustment: During treatment, the doctor will adjust the dose according to the patient's disease status and drug tolerance. For patients who experience serious adverse reactions or specific side effects, a dose reduction or treatment suspension may be necessary to reduce discomfort and protect the patient's health.

5.Monitoring and adjustment: During treatment, doctors will regularly conduct clinical evaluations, imaging examinations and laboratory tests on patients to monitor the progression of the disease and the effect of treatment. Depending on the patient's specific condition, the doctor may adjust the dosage or take other treatment measures.

6.Adverse reactions:Osimertinib/OsimertinibCommon adverse reactions include rash, diarrhea, drowsiness, fatigue, cough, etc. Serious adverse reactions may include interstitial pneumonia, cardiovascular events, visual impairment, etc. Patients should pay close attention to their own conditions during medication and report any symptoms of discomfort to their doctors in a timely manner.

7.Medication for special populations: For special populations, such as elderly patients, patients with impaired liver function, patients with impaired renal function and pregnant women, osimertinib/osimertinib should be used with caution, and the dose should be adjusted according to the specific situation. For patients with impaired hepatic function, a dose reduction may be necessary; for patients with impaired renal function, dose adjustment is generally not required; pregnant women should avoid exposure to osimertinib/osimertinib due to the potential for harm to the fetus.

8.Follow the doctor's advice and conduct regular follow-up visits: Patients should strictly abide by the doctor's recommendations and instructions during medication, conduct regular follow-up visits, and promptly report any symptoms of discomfort to ensure the safety and effectiveness of treatment. Doctors will make adjustments based on the patient's disease status and drug tolerance, and provide patients with necessary support and guidance.

9.Interactions: During medication, patients should avoid interactions with other drugs, especially CYP3A4 and P-gp span> inhibitors and inducers, so as not to affect the pharmacokinetics of osimertinib/osimertinib.

In summary, the dosage guidelines for osimertinib/osimertinib are crucial to the patient's therapeutic effect. Patients should use osimertinib correctly under the guidance of a doctor, and have regular follow-up visits and report any adverse reactions in a timely manner to ensure the smooth progress of treatment, improve treatment effects, and improve the quality of life.